Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Decline in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 16,557 shares, a drop of 89.3% from the May 31st total of 154,973 shares. Based on an average daily trading volume, of 233,740 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.1% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Silexion Therapeutics currently has a consensus rating of “Hold”.

Silexion Therapeutics Stock Performance

Shares of Silexion Therapeutics stock opened at $2.73 on Friday. Silexion Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $223.60. The company has a market capitalization of $1.15 million, a P/E ratio of -0.03 and a beta of -0.32. The company has a fifty day moving average of $5.36 and a 200 day moving average of $13.93.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($12.90) by $12.05. Analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.